Skip to main content
ALMS
NASDAQ Life Sciences

Foresite Capital and Director Tananbaum Invest $10.6M in Alumis Stock

Analyse IA par Wiseek
Sentiment info
Positif
Importance info
8
Prix
$21.08
Cap. de marche
$2.574B
Plus bas 52 sem.
$2.76
Plus haut 52 sem.
$22.3
Market data snapshot near publication time

summarizeResume

This Schedule 13D/A filing reveals that Foresite Capital, a major institutional shareholder, and James B. Tananbaum, a director of Alumis Inc. and managing member of Foresite entities, have significantly increased their beneficial ownership. The group acquired approximately $3.6 million in open market purchases in November 2025 and an additional $7.0 million in the company's follow-on offering on January 8, 2026. These substantial investments, totaling around $10.6 million, demonstrate strong conviction from a key investor and insider, particularly following a period of dilution. The participation in the follow-on offering at $17.00 per share, compared to the current stock price of $21.08, suggests confidence in the company's valuation and future prospects.


check_boxEvenements cles

  • Significant Insider/Institutional Purchases

    Foresite Capital and director James B. Tananbaum acquired approximately $10.6 million worth of Alumis Inc. common stock.

  • Follow-on Offering Participation

    The group purchased $7.0 million in shares at $17.00 per share as part of the company's January 8, 2026 follow-on offering.

  • Open Market Acquisitions

    An additional $3.6 million in shares were acquired through open market purchases in November 2025.

  • Increased Beneficial Ownership

    The reporting persons collectively hold 14.1% of Alumis Inc.'s common stock.


auto_awesomeAnalyse

This Schedule 13D/A filing reveals that Foresite Capital, a major institutional shareholder, and James B. Tananbaum, a director of Alumis Inc. and managing member of Foresite entities, have significantly increased their beneficial ownership. The group acquired approximately $3.6 million in open market purchases in November 2025 and an additional $7.0 million in the company's follow-on offering on January 8, 2026. These substantial investments, totaling around $10.6 million, demonstrate strong conviction from a key investor and insider, particularly following a period of dilution. The participation in the follow-on offering at $17.00 per share, compared to the current stock price of $21.08, suggests confidence in the company's valuation and future prospects.

Au moment de ce dépôt, ALMS s'échangeait à 21,08 $ sur NASDAQ dans le secteur Life Sciences, pour une capitalisation boursière d'environ 2,6 Md $. La fourchette de cours sur 52 semaines allait de 2,76 $ à 22,30 $. Ce dépôt a été évalué avec un sentiment de marché positif et un score d'importance de 8 sur 10.

descriptionVoir le depot SEC principal

show_chartGraphique des prix

Partager cet article

Copied!

feed ALMS - Dernieres analyses

ALMS
Mar 30, 2026, 6:06 AM EDT
Filing Type: 8-K
Importance Score:
9
ALMS
Mar 19, 2026, 5:02 PM EDT
Filing Type: S-3ASR
Importance Score:
7
ALMS
Mar 19, 2026, 4:23 PM EDT
Filing Type: 10-K
Importance Score:
8
ALMS
Mar 19, 2026, 4:12 PM EDT
Filing Type: 8-K
Importance Score:
9
ALMS
Mar 19, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
9
ALMS
Jan 13, 2026, 6:20 PM EST
Filing Type: 4
Importance Score:
7
ALMS
Jan 13, 2026, 6:18 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
7
ALMS
Jan 12, 2026, 9:59 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
8
ALMS
Jan 09, 2026, 6:02 AM EST
Filing Type: 8-K
Importance Score:
8
ALMS
Jan 08, 2026, 5:29 PM EST
Filing Type: 424B5
Importance Score:
8